Deep product pipeline of T2MR® applications in development

T2 Biosystems has multiple applications currently in development that may enable breakthroughs in providing more rapid and accurate therapy to patients. All are focused on high-value healthcare ailments where solutions can serve a dual role: saving lives while reducing costs. Due to the T2 Magnetic Resonance (T2MR) advantage of detecting directly from patient blood samples, there is an opportunity for significant clinical advantages and market impact. 

Product Pipeline Highlights 

In addition to our FDA-cleared T2Candida® Panel and T2Dx® Instrument, and the CE Marked T2Bacteria® Panel, new products in the pipeline include additional sepsis, hemostasis and Lyme disease applications, as shown in the chart above.

T2HemoStat™ Panel Comprehensive hemostasis profiling for trauma patients at the point of care

T2Plex™ Instrument  Compact, fully-integrated instrument for providing rapid hemostasis measurements at the point of care 

T2Lyme™ Panel – T2 Biosystems and Canon US Life Sciences have partnered to develop a rapid diagnostic for Lyme disease

1. This page contains T2's future goals and aspirations, which constitute forward-looking statement that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. See "Forward-Looking Statements" and the factors discussed under Item 1A. "Risk Factors" in the company's most recent Annual Report on Form 10-K for the prior fiscal year, filed with the U.S. Securities and Exchange Commission, or SEC, and other filings the company makes with the SEC from time to time.
The T2Dx Instrument and T2Candida Panel have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.